Mainstream

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements

Post ContentadptRead More

You might also be interested in reading DXC Technology raises FY26 EPS guidance to $2.85-$3.35 as AI initiatives and bookings momentum continue.

February 12, 2025
In Mainstream